|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase Ⅱ trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin显示文摘 | Patt YZ Hoque A Lozano R | 1997 | Jpn Clin Oncol1997，15，4： | 1 |
| 2 | Capecitabine plus 3- weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase Ⅱ trial results显示文摘 | Patt YZ Lee FC Liebmann JE | 2007 | Am JClin Oncol2007，30，4： | 1 |
| 3 | Oral capecit- abine for the treatment of hepatocellar carcinoma, cholangio- carcinoma, and gallbladder carcinoma 显示文摘 | PATT YZ HASSAN MM AGUAYO A | 2004 | Cancer2004，101，3： | 1 |
| 4 | Modified cisplatin/interferon a-2b/doxombicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellu- lar carcinoma显示文摘 | Kaseb AO Shindoh J Patt YZ | 2013 | Cancer2013，119，18： | 1 |
| 5 | Oral capecitabine for the treatment of hepatocellular carcinoma,cholangiocinoma,and gallbladdercarcinoma显示文摘 | Patt YZ Hassan MM Aguayo A | 2004 | Cancer2004，101，3： | 1 |
| 6 | Oral capecitabinc for the treatment of hepatocellular carcinoma, cholangioearcinoma, and gallbladder carcinoma显示文摘 | Patt YZ Hassan MM Aguayo A | 2004 | Cancer2004，101，： | 1 |
| 7 | Oral capecilabine for the trealmenl of hepatocellular carcinoma,cholangiocarcinoma,and gallbladder carcinoma显示文摘 | Patt YZ Hassan MM Aguayo A | 2004 | Cancer2004，101，3： | 1 |
| 8 | Capecitabine plus 3- weekly irinotecan (XELIR! regimen) as first-line chemotherapy for metastatic colorectal cancer:phase I1 trial results 显示文摘 | Patt YZ Lee FC Liebmann JE | 2007 | Am J Clin Oncol2007，30，： | 1 |
| 9 | Oral capecitabine for the treatment of hepatocellular carcinoma,cholangiocarcinoma,and gallbladder carcinoma显示文摘 | Patt YZ Hassan MM Aguayo A | 2004 | Cancer2004，101，3： | 1 |
| 10 | Phase Ⅱ trial of cisplatin,interferon alpha-2b,doxorubicin,and 5-fluorouracil for biliary tract cancer显示文摘 | Patt YZ Hassan MM Lozano RD | 2001 | Clin Cancer Res2001，7，11： | 1 |
| 11 | Oral capecitabine for the treatment of hepatocellular carcinoma,cholangiocarcinoma,and gallbladder carcinoma显示文摘 | Patt YZ Hassan MM Aguayo A | 2004 | Cancer2004，，： | 1 |
| 12 | Hepatic arterial infusion of PUDR, Leucovorin, Adriamycin and platinol (FLAP) : effective pallialion for non-resectable hepatocellular cancer显示文摘 | Patt YZ Charnsangavej C Lawrence D | 1992 | Proc Ann Meet Anl Soc Clin Oncol1992，11，： | 1 |
| 13 | Capecitabine plus 3- weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase Ⅱ trial results 显示文摘 | Patt YZ Lee FC Liebmann JE | 2007 | Am J Clin Oncol2007，30，4： | 1 |
| 14 | Nonsurgical treatment of hepatocellular carcinoma显示文摘 | Aguayo A Patt YZ | 2001 | Semin Oncol2001，28，5： | 1 |
| 15 | Thalidomide in the treatment of patients with hepatocellular carcinoma - A phase II trial 显示文摘 | Patt YZ Hassan MM Lozano RD | 2005 | Cancer2005，103，4： | 1 |
| 16 | Phase Ⅱ trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma显示文摘 | Patt YZ Hassan MM Lozano RD | 2003 | J Clin Oncol2003，21，： | 1 |
| 17 | Oral capecitabine for the treatment of hepatocellular carcinoma,cholangiocarcinoma, and gallbladder carcinoma 显示文摘 | Patt YZ Hassan MM Aguayo A | 2004 | Cancer2004，101，3： | 1 |
| 18 | Capeeitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase Ⅱ trial results显示文摘 | Patt YZ Lee FC Liebmann JE | 2007 | Am J Clin Oncol2007，30，4： | 1 |
| 19 | Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma显示文摘 | Leung TW Patt YZ Lau WY | 1999 | Clin Cancer Res1999，5，7： | 1 |
| 20 | Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma显示文摘 | Patt YZ Hassan MM Aguayo A | 2004 | Cancer2004，101，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员